How Close are We to a COVID-19 Vaccine?
subject: immune response, Recombinant, COVID-19 vaccine, atteneu virus, phase studies
description: This review provides an overview regarding the main aspects of candidate COVID-19 vaccines andpathophysiology of disease. The types of biotechnological candidate vaccines to be developedagainst COVID-19, their degree of protection and the pathophysiological mechanism of the diseasewere analyzed in this review article. The literature data on which cruxes for the development ofbiotechnological candidate vaccines to be wended are based was researched. Data that could givereference to various biotechnological candidate vaccines were reviewed. For this purpose, up-todate literature data was utilized. The ways to succeed in the development of a vaccine requiring atechnological infrastructure are to synthesize the data obtained from long term trials and to put theminto practice subsequently. The vaccines to be developed by means of recombinant DNA technology willbe a source of inspiration to people for further studies. After a rapid process of vaccine development,the use of COVID-19 vaccine can be mainstreamed among people to prevent the disease. As a resultof these practices, the evaluation of which vaccine will be more safe, reliable and effective will beperformed after phase studies.
creator: Kayhan Ozkan
source: Journal of Pure and Applied Microbiology
publisher: Journal of Pure and Applied Microbiology
date: 2020
identifier: DOI: 10.22207/JPAM.14.SPL1.26
coverage: Microbiology